Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 61Stomach Neoplasms 46Colorectal Neoplasms 24Esophageal Squamous Cell Carcinoma 19Rectal Neoplasms 11Esophageal Neoplasms 11Pancreatic Neoplasms 7Cholangiocarcinoma 6Liver Neoplasms 5Colonic Neoplasms 4Neoplasms 3Colorectal Cancer Metastatic 3Spinocerebellar Degenerations 2Neoplasm Metastasis 2Locally Advanced Rectal Cancer 2Liver Diseases 2Gastric Adenocarcinoma 2Advanced Biliary Tract Cancer 2Uterine Cervical Neoplasms 1Unresectable Locally Advanced Pancreatic Cancer 1Turcot syndrome 1Tislelizumab 1Small Cell Lung Carcinoma 1Recurrence 1Pancreatic Cancer Resectable 1Pancreatic Cancer Metastatic 1PD-1 Antibody 1Ovarian Neoplasms 1Neoplasms, Squamous Cell 1Microsatellite Stable Metastatic Colorectal Cancer 1

Interventions

S 1 (combination) 2tislelizumab 1sintilimab 1Paclitaxel 1Hyperthermic Intraperitoneal Chemotherapy 1Doxorubicin 1Cisplatin 1Bevacizumab 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gastric Cancer Peritoneal Metastases × sintilimab × Gastrointestinal × Clear all
NCT06487715 2024-07-05

Safety and Efficacy of Systemic Chemotherapy Plus PD-1 Inhibitor in Combination With Bevacizumab in Gastric Cancer With Peritoneal Metastasis

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 2 Unknown
42 enrolled
Gastrointestinal

Gastric Cancer Peritoneal Metastases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡